Evidence map›Paper›PMID 40359993›Full record

ReviewOpen biology2025

Cancer cells' chamber of secrets: the link between micronuclei, chromothripsis and malignancy.

Truman Raleigh Mcneil, Sweta Sikder, Yamini Dalal

Abstract readReview
In one paragraph

Review in Open biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Metabolic Profiling of DistinctInternational journal of molecular sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Truman Raleigh McneilCenter for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Sweta SikderCenter for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Yamini DalalCenter for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.ORCID 0000-0002-7655-6182

Funding

NCI NIH HHS
6 · The paper itself

Abstract

Micronuclei exhibit defective proteomes rendering their chromatin vulnerable to fragmentation. This fragmentation process, known as chromothripsis, promotes tumorigenesis by catalysing the activation of oncogenes and the silencing of tumor suppressors. With this role in mind, micronuclei serve as promising targets for therapeutic intervention. This review will explore recent discoveries regarding how micronuclei form, their function in catalysing chromothripsis and how chromothripsis provides a selective advantage for cancer cells.

Indexed as

ChromothripsisMicronuclei, Chromosome-DefectiveNeoplasmsAnimalsChromatinHumansChromatincancerchromosomal instabilitychromothripsismicronucleimitotic defectstumorigenesis

Identifiers

PMID40359993
PMCPMC12225691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.